Testing levetiracetam's effect on brain function in psychosis risk
Treatments studied
Part of Mental health clinical trials.
This trial tests whether a single dose of levetiracetam, a medication that affects brain chemistry, can change brain function and thinking in people at risk for psychosis. The goal is to see if it might help prevent symptoms from worsening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 40 years old.
- You must have mild symptoms that suggest you might be at risk for psychosis (as assessed by a study doctor).
- You cannot have had a full episode of psychosis in the past.
- You cannot be taking certain medications like benzodiazepines, antipsychotics, or mood stabilizers.
- You must be able to have an MRI scan (no metal implants, claustrophobia issues, etc.).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a cognitive training program can help young adults with recent psychosis improve their thinking and memory skills. It involves brain scans and cognitive exercises.
This trial tests whether a personalized care plan improves day-to-day functioning for people in the early stages of psychosis. It aims to see if adding structured support after a recent diagnosis can help you function better.
This trial tests if a medication called levetiracetam (a drug usually used for seizures) can help protect memory in people who are at higher risk for Alzheimer's but do not yet have memory problems. It involves brain scans and cognitive tests to see if the drug can reduce overactive brain activity linked to memory loss.
This Phase 2 study tests whether AGB101 (levetiracetam) can reduce hallucinations, delusions, or related symptoms in people with Parkinson’s disease psychosis, while checking safety. You and a study partner will help with dosing and regular check-ins, including MRI scans.
This Phase 2 study tests whether an added medication strategy can change brain targets linked to memory decline in people with Parkinson’s disease, including those with no memory problems or mild memory changes. It may help lower risk of developing dementia, but you must be able to safely do MRI scans and meet other health and medication rules.
This trial tests if cannabidiol (a non-psychoactive cannabis component) can prevent psychosis in people ages 12-35 at high risk. It compares CBD to a placebo to see if it reduces symptoms and delays or prevents a first psychotic episode.
Hear when a new Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.